Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
| Brand name | VALSARTAN |
| Generic name | VALSARTAN |
| Active ingredient(s) | VALSARTAN |
| Distributed by / for | Camber Pharmaceuticals, Inc. Piscataway NJ 08854 By: Hetero Hetero Labs Limited, Unit V, Pollepally Jadcherla Mahabubnagar - 509-301, India |
| NDC | 31722-747-90 |
| Full product label | Camber Pharmaceuticals, Inc. Valsartan Tablets, USP, 160 mg, 90 tablets Rx Only Manufactured for: Camber Pharmaceuticals, Inc. Piscataway NJ 08854 By: Hetero Hetero Labs Limited, Unit V, Pollepally Jadcherla Mahabubnagar - 509-301, India. NDC 31722-747-90 UPC 331722747905 |
| Recalling firm | Hetero Labs Limited Unit V |
| Distribution | Nationwide |
| Quantity | 441,408 bottles |
| Recall initiated | 2018-08-08 |
| Report date | 2018-08-29 |
| Recall completed | — |
| Recall number | D-1115-2018 |
| Classification | Class II |
| FDA status | Completed |
| Origin on file | Jadcherla Mandal, Mahaboob Nagar India |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗